Retatrutide, also called LY3437943, is being studied as a triple agonist that acts on GLP-1, GIP, and glucagon receptors
Track specific markers including pain levels (using a consistent 0-10 scale), range of motion, visible swelling, and functional capacity
A New Line Item Americans Won't Cut The findings show that GLP-1 medication has moved from the "nice to have" column into the "non-negotiable" one for many of the people taking it
van Rijn MJ, Slooter AJ, Bos MJ, Catarino CF, Koudstaal PJ, Hofman A, et al
Rare but serious complications, such as vascular occlusion, can occur if filler inadvertently enters a blood vessel
The way patients perceive changes in their treatment can have a significant impact on outcomes, as some may delay seeking medical advice or adjusting their treatment regimen without consulting a healthcare professional